Cornelia Mauch

Assistant professor

university hospital of the ruhr university bochum
Country flagGermany
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

PFS in ( A ) part I/run-in and ( B ) part II. A, Kaplan–Meier analysis of PFS with encorafenib plus binimetinib in naïve and pretreated patients in the FAS population. B, Kaplan–Meier analysis of PFS in the encorafenib plus binimetinib and ribociclib, encorafenib plus binimetinib and capmatinib, and encorafenib plus binimetinib and buparlisib arms.

Year:

2025

Purpose: LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study, assessed encorafenib plus binimetinib combined with a third targeted agent after tumor progression on encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. Patients and Methods: Adults with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma who were BRAF inhibitor/MEK inhibitor (BRAFi/MEKi) treatment–naïve or pretreated received encorafenib plus binimetinib (part I/run-in). Based on the genomic testing at disease progression following encorafenib plus binimetinib, patients were assigned to one of four treatment arms to receive encorafenib plus binimetinib with an appropriate molecularly targeted agent (ribociclib, infigratinib, capmatinib, or buparlisib; part II). The primary endpoint was best overall response; safety, biomarkers, pharmacokinetics, and other efficacy endpoints were also assessed. Results: In part I/run-in, 75 BRAFi/MEKi-naïve patients and 83 BRAFi/MEKi-pretreated patients were treated; in part II, 58 patients were treated (ribociclib, n = 38; infigratinib, n = 1; capmatinib, n = 13; buparlisib, n = 6). The overall confirmed response rate was 73.3% [95% confidence interval (CI), 61.9–82.9] in BRAFi/MEKi-naïve patients, 25.3% (95% CI, 16.4–36.0) in pretreated patients, 2.6% (95% CI, 0.1–13.8) in the ribociclib arm, and 0% in the other three arms. Adverse events were manageable and consistent with the known safety profile of each drug. Conclusions: LOGIC 2 supports the use of encorafenib plus binimetinib for treatment-naïve and previously treated, locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. However, adding a third targeted agent following disease progression did not show meaningful efficacy; further research is needed to identify other therapeutic targets to circumvent resistance.

Year:

2025

LOGIC 2 study design. A multicenter, open-label, two-part, phase II study to assess the efficacy and safety of encorafenib plus binimetinib (part I) followed by encorafenib plus binimetinib combined with a third targeted agent after tumor progression (part II) in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma. a Single agents include vemurafenib, dabrafenib, encorafenib, trametinib, and binimetinib; combinations include dabrafenib/trametinib and encorafenib/binimetinib. b Patients who experienced PD on a prior BRAFi/MEKi regimen continued encorafenib/binimetinib if a PR was observed followed by a new biopsy at progression. Patients who did not progress on their prior regimen could continue the encorafenib/binimetinib combination until evidence of PD, at which point a tumor biopsy would be taken and analyzed to guide assignment to a triplet combination arm in part II.

Year:

2025

Collaborators (10)

Jessica C. Hassel

Heidelberg University

GERMANY
View details

Reinhard Dummer

University Hospital of Zurich

SWITZERLAND
View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Marcus Butler

University Health Network

CANADA
View details

Wilson H Miller Jr

McGill University

CANADA
View details

Michael A. Postow

Weill Cornell Medical College

UNITED STATES
View details

Lucie Heinzerling

University Hospital

GERMANY
View details

Shahneen Sandhu

-

AUSTRALIA
View details

Mark Middleton

University of Oxford

UNITED KINGDOM
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details